Editorial Comment on “Efficacy of pembrolizumab plus lenvatinib as first‐line treatment for metastatic renal cell carcinoma with multiple brain metastases”

Saved in:
Bibliographic Details
Main Author: Manabu Kato
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:IJU Case Reports
Online Access:https://doi.org/10.1002/iju5.12805
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846098532611653632
author Manabu Kato
author_facet Manabu Kato
author_sort Manabu Kato
collection DOAJ
format Article
id doaj-art-0c52cc90e5a54c26b89e7e328bb037b7
institution Kabale University
issn 2577-171X
language English
publishDate 2025-01-01
publisher Wiley
record_format Article
series IJU Case Reports
spelling doaj-art-0c52cc90e5a54c26b89e7e328bb037b72025-01-01T23:35:59ZengWileyIJU Case Reports2577-171X2025-01-018191010.1002/iju5.12805Editorial Comment on “Efficacy of pembrolizumab plus lenvatinib as first‐line treatment for metastatic renal cell carcinoma with multiple brain metastases”Manabu Kato0Department of Urology Aichi Cancer Center Hospital Nagoya Aichi Japanhttps://doi.org/10.1002/iju5.12805
spellingShingle Manabu Kato
Editorial Comment on “Efficacy of pembrolizumab plus lenvatinib as first‐line treatment for metastatic renal cell carcinoma with multiple brain metastases”
IJU Case Reports
title Editorial Comment on “Efficacy of pembrolizumab plus lenvatinib as first‐line treatment for metastatic renal cell carcinoma with multiple brain metastases”
title_full Editorial Comment on “Efficacy of pembrolizumab plus lenvatinib as first‐line treatment for metastatic renal cell carcinoma with multiple brain metastases”
title_fullStr Editorial Comment on “Efficacy of pembrolizumab plus lenvatinib as first‐line treatment for metastatic renal cell carcinoma with multiple brain metastases”
title_full_unstemmed Editorial Comment on “Efficacy of pembrolizumab plus lenvatinib as first‐line treatment for metastatic renal cell carcinoma with multiple brain metastases”
title_short Editorial Comment on “Efficacy of pembrolizumab plus lenvatinib as first‐line treatment for metastatic renal cell carcinoma with multiple brain metastases”
title_sort editorial comment on efficacy of pembrolizumab plus lenvatinib as first line treatment for metastatic renal cell carcinoma with multiple brain metastases
url https://doi.org/10.1002/iju5.12805
work_keys_str_mv AT manabukato editorialcommentonefficacyofpembrolizumabpluslenvatinibasfirstlinetreatmentformetastaticrenalcellcarcinomawithmultiplebrainmetastases